Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

E David Crawford

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Radiation Oncology
Phone303/298-1662

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Petrylak DP, Crawford ED. Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. Target Oncol. 2017 Jun 16. PMID: 28620691.
      View in: PubMed
    2. Stone NN, Mouraviev V, Schechter D, Lucia MS, Smith EE, Arangua P, Hoenemeyer J, Rosa J, Bawa R, Crawford ED. The 3DBiopsy Prostate Biopsy System: Preclinical Investigation of a Needle, Actuator and Specimen Collection Device Allowing Sampling of Individualized Prostate Lengths between 20 and 60 mm. Urology. 2017 Jun 07. PMID: 28601561.
      View in: PubMed
    3. Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJR, Marshall DC. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017 May; 35(5):183-191. PMID: 28325650.
      View in: PubMed
    4. Crawford ED, Petrylak DP, Shore N, Saad F, Slovin SF, Vogelzang NJ, Keane TE, Koo PJ, Gomella LG, O'Sullivan JM, Tombal B, Concepcion RS, Sieber P, Stone NN, Finkelstein SE, Yu EY. The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology. 2017 Jun; 104:150-159. PMID: 28302580.
      View in: PubMed
    5. Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 Jun; 35(6):438-446. PMID: 28214281.
      View in: PubMed
    6. Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15; 123(4):592-599. PMID: 27911486.
      View in: PubMed
    7. Kim EH, Andriole GL, Crawford ED, Sjoberg DD, Assel M, Vickers AJ, Lilja H. Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. J Urol. 2017 Apr; 197(4):1041-1047. PMID: 27810449.
      View in: PubMed
    8. Stone NN, Mouraviev V, Schechter D, Goetz J, Lucia MS, Smith EE, Crawford ED. Deflection Analysis of Different Needle Designs for Prostate Biopsy and Focal Therapy. Technol Cancer Res Treat. 2016 Oct 05. PMID: 27708117.
      View in: PubMed
    9. Werahera PN, Jasion EA, Crawford ED, Lucia MS, van Bokhoven A, Sullivan HT, Kim FJ, Maroni PD, Port JD, Daily JW, La Rosa FG. Diffuse reflectance spectroscopy can differentiate high grade and low grade prostatic carcinoma. Conf Proc IEEE Eng Med Biol Soc. 2016 Aug; 2016:5148-5151. PMID: 28325017.
      View in: PubMed
    10. Catarinicchia SP, Crawford ED. Prostate cancer: Testosterone therapy for hypogonadal men with prostate cancer. Nat Rev Urol. 2016 Sep; 13(9):497-8. PMID: 27431338.
      View in: PubMed
    11. Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM, Carroll P, Eastham J, Gomella L, Klein EA. An Approach Using PSA Levels of 1.5?ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. 2016 Oct; 96:116-120. PMID: 27450937.
      View in: PubMed
    12. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, Mahmood U, Chen RC, Chapin BF, Kavanagh BD, Pugh TJ. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 Aug 20; 34(24):2835-42. PMID: 27325855.
      View in: PubMed
    13. Catarinicchia S, Crawford ED. The Role of FSH in Prostate Cancer: A Case Report. Urol Case Rep. 2016 Jul; 7:23-5. PMID: 27335783; PMCID: PMC4909606.
    14. Sutton SS, Crawford ED, Moul JW, Hardin JW, Kruep E. Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System. World J Urol. 2016 Aug; 34(8):1107-13. PMID: 26753559.
      View in: PubMed
    15. Crawford ED, Albala DM, Wysocki JS, Lepor H, Ross AE, Finkelstein SE, Keane T, Freedland S, Harris R, Shore ND, Ryan CJ. Prostate Cancer Academy 2016: Presentation summaries. Rev Urol. 2016; 18(4):205-213. PMID: 28127262.
      View in: PubMed
    16. Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Can J Urol. 2015 Dec; 22(6):8048-55. PMID: 26688132.
      View in: PubMed
    17. Shore ND, Kella N, Moran B, Boczko J, Bianco FJ, Crawford ED, Davis T, Roundy KM, Rushton K, Grier C, Kaldate R, Brawer MK, Gonzalgo ML. Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. J Urol. 2016 Mar; 195(3):612-8. PMID: 26403586.
      View in: PubMed
    18. Crawford ED, Poage W, Nyhuis A, Price DA, Dowsett SA, Gelwicks S, Muram D. Measurement of testosterone: how important is a morning blood draw? Curr Med Res Opin. 2015; 31(10):1911-4. PMID: 26360789.
      View in: PubMed
    19. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. J Urol. 2015 Dec; 194(6):1537-47. PMID: 26196735.
      View in: PubMed
    20. Crawford ED, Poage W, Nyhuis A, Price DA, Dowsett SA, Muram D. Effects of Testosterone Level on Lower Urinary Tract Symptoms. Am J Mens Health. 2016 Sep; 10(5):440-2. PMID: 26077271.
      View in: PubMed
    21. Shore ND, Karsh L, Gomella LG, Keane TE, Concepcion RS, Crawford ED. Avoiding obsolescence in advanced prostate cancer management: a guide for urologists. BJU Int. 2015 Feb; 115(2):188-97. PMID: 25756134.
      View in: PubMed
    22. Pokharel SS, Patel NU, Garg K, La Rosa FG, Arangua P, Jones C, Crawford ED. Multi-parametric MRI findings of transitional zone prostate cancers: correlation with 3-dimensional transperineal mapping biopsy. Abdom Imaging. 2015 Jan; 40(1):143-50. PMID: 25038718.
      View in: PubMed
    23. Stone NN, Crawford ED. To screen or nor to screen: the prostate cancer dilemma. Asian J Androl. 2015 Jan-Feb; 17(1):44-5. PMID: 25337849; PMCID: PMC4291875.
    24. Werahera PN, Jasion EA, Liu Y, Daily JW, Arangua P, Jones C, Nash SR, Morrell M, Crawford ED. Human feasibility study of fluorescence spectroscopy guided optical biopsy needle for prostate cancer diagnosis. Conf Proc IEEE Eng Med Biol Soc. 2015; 2015:7358-61. PMID: 26737991.
      View in: PubMed
    25. Crawford ED, Moul JW. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. Oncology (Williston Park). 2015 Jan; 29(1):55-8, 65-6. PMID: 25592210.
      View in: PubMed
    26. Crawford ED, Moul JW, Sartor O, Shore ND. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Metab Toxicol. 2015; 11(9):1465-74. PMID: 26293510.
      View in: PubMed
    27. Bourlon MT, Glodé LM, Crawford ED. Base of the skull metastases in metastatic castration-resistant prostate cancer. Oncology (Williston Park). 2014 Dec; 28(12):1115-6, 1124. PMID: 25510811.
      View in: PubMed
    28. Crawford ED, Persson BE, Klotz L. Reply by the authors. Urology. 2014 Nov; 84(5):1250-1. PMID: 25443944.
      View in: PubMed
    29. Stone NN, Unger P, Crawford ED, Stock RG. Diagnosis and management of local recurrence after low-dose-rate brachytherapy. Brachytherapy. 2015 Mar-Apr; 14(2):124-30. PMID: 25239396.
      View in: PubMed
    30. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A, Kaaks R, Kamat AM, Kamineni A, Karagas M, Khanna C, Khaw KT, Kim C, Kim IS, Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC, Lecanda F, Lee KM, Lee MP, Le Marchand L, Lerner SP, Li D, Liao LM, Lim WY, Lin D, Lin J, Lindstrom S, Linet MS, Lissowska J, Liu J, Ljungberg B, Lloreta J, Lu D, Ma J, Malats N, Mannisto S, Marina N, Mastrangelo G, Matsuo K, McGlynn KA, McKean-Cowdin R, McNeill LH, McWilliams RR, Melin BS, Meltzer PS, Mensah JE, Miao X, Michaud DS, Mondul AM, Moore LE, Muir K, Niwa S, Olson SH, Orr N, Panico S, Park JY, Patel AV, Patino-Garcia A, Pavanello S, Peeters PH, Peplonska B, Peters U, Petersen GM, Picci P, Pike MC, Porru S, Prescott J, Pu X, Purdue MP, Qiao YL, Rajaraman P, Riboli E, Risch HA, Rodabough RJ, Rothman N, Ruder AM, Ryu JS, Sanson M, Schned A, Schumacher FR, Schwartz AG, Schwartz KL, Schwenn M, Scotlandi K, Seow A, Serra C, Serra M, Sesso HD, Severi G, Shen H, Shen M, Shete S, Shiraishi K, Shu XO, Siddiq A, Sierrasesumaga L, Sierri S, Loon Sihoe AD, Silverman DT, Simon M, Southey MC, Spector L, Spitz M, Stampfer M, Stattin P, Stern MC, Stevens VL, Stolzenberg-Solomon RZ, Stram DO, Strom SS, Su WC, Sund M, Sung SW, Swerdlow A, Tan W, Tanaka H, Tang W, Tang ZZ, Tardon A, Tay E, Taylor PR, Tettey Y, Thomas DM, Tirabosco R, Tjonneland A, Tobias GS, Toro JR, Travis RC, Trichopoulos D, Troisi R, Truelove A, Tsai YH, Tucker MA, Tumino R, Van Den Berg D, Van Den Eeden SK, Vermeulen R, Vineis P, Visvanathan K, Vogel U, Wang C, Wang C, Wang J, Wang SS, Weiderpass E, Weinstein SJ, Wentzensen N, Wheeler W, White E, Wiencke JK, Wolk A, Wolpin BM, Wong MP, Wrensch M, Wu C, Wu T, Wu X, Wu YL, Wunder JS, Xiang YB, Xu J, Yang HP, Yang PC, Yatabe Y, Ye Y, Yeboah ED, Yin Z, Ying C, Yu CJ, Yu K, Yuan JM, Zanetti KA, Zeleniuch-Jacquotte A, Zheng W, Zhou B, Mirabello L, Savage SA, Kraft P, Chanock SJ, Yeager M, Landi MT, Shi J, Chatterjee N, Amundadottir LT. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33. PMID: 25027329; PMCID: PMC4240198.
    31. Crawford ED, Persson BE. Re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.01.026. Eur Urol. 2014 Aug; 66(2):e34-5. PMID: 24768492.
      View in: PubMed
    32. Rove KO, Crawford ED, Perachino M, Morote J, Klotz L, Lange PH, Andriole GL, Matsumoto AM, Taneja SS, Eisenberger MA, Reis LO. Maximal testosterone suppression in prostate cancer--free vs total testosterone. Urology. 2014 Jun; 83(6):1217-22. PMID: 24713136; PMCID: PMC4332796.
    33. Rove KO, Crawford ED. Traditional androgen ablation approaches to advanced prostate cancer: new insights. Can J Urol. 2014 Apr; 21(2 Supp 1):14-21. PMID: 24775719.
      View in: PubMed
    34. Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1064-73. PMID: 24661660.
      View in: PubMed
    35. Crawford ED, Shore ND, Moul JW, Tombal B, Schröder FH, Miller K, Boccon-Gibod L, Malmberg A, Olesen TK, Persson BE, Klotz L. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology. 2014 May; 83(5):1122-8. PMID: 24661333.
      View in: PubMed
    36. Barqawi AB, Stoimenova D, Krughoff K, Eid K, O'Donnell C, Phillips JM, Crawford ED. Targeted focal therapy for the management of organ confined prostate cancer. J Urol. 2014 Sep; 192(3):749-53. PMID: 24641910.
      View in: PubMed
    37. Crawford ED, Scholz MC, Kar AJ, Fegan JE, Haregewoin A, Kaldate RR, Brawer MK. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014 Jun; 30(6):1025-31. PMID: 24576172.
      View in: PubMed
    38. Crawford ED, Ventii K, Shore ND. New biomarkers in prostate cancer. Oncology (Williston Park). 2014 Feb; 28(2):135-42. PMID: 24701701.
      View in: PubMed
    39. Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, Malmberg A, Persson BE. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014 Dec; 66(6):1101-8. PMID: 24440304.
      View in: PubMed
    40. Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014 Mar; 83(3):664-9. PMID: 24411213.
      View in: PubMed
    41. Shui IM, Lindström S, Kibel AS, Berndt SI, Campa D, Gerke T, Penney KL, Albanes D, Berg C, Bueno-de-Mesquita HB, Chanock S, Crawford ED, Diver WR, Gapstur SM, Gaziano JM, Giles GG, Henderson B, Hoover R, Johansson M, Le Marchand L, Ma J, Navarro C, Overvad K, Schumacher FR, Severi G, Siddiq A, Stampfer M, Stevens VL, Travis RC, Trichopoulos D, Vineis P, Mucci LA, Yeager M, Giovannucci E, Kraft P. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun; 65(6):1069-75. PMID: 24411283; PMCID: PMC4006298.
    42. Werahera PN, Jasion EA, Crawford ED, La Rosa FG, Lucia MS, van Bokhoven A, Sullivan HT, Port JD, Maroni PD, Daily JW. Systematic diagnosis of prostate cancer using an optical biopsy needle adjunct with fluorescence spectroscopy. Conf Proc IEEE Eng Med Biol Soc. 2014; 2014:2165-8. PMID: 25570414.
      View in: PubMed
    43. Krughoff K, Eid K, Phillips J, Stoimenova D, Smith D, O'Donnell C, Crawford ED, Barqawi A. The accuracy of prostate cancer localization diagnosed on transrectal ultrasound-guided biopsy compared to 3-dimensional transperineal approach. Adv Urol. 2013; 2013:249080. PMID: 24470798; PMCID: PMC3891607.
    44. Werahera PN, Crawford ED, La Rosa FG, Torkko KC, Schulte B, Sullivan HT, van Bokhoven A, Lucia MS, Kim FJ. Anterior tumors of the prostate: diagnosis and significance. Can J Urol. 2013 Oct; 20(5):6897-906. PMID: 24128826; PMCID: PMC4676571.
    45. Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP. The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013 Sep; 112(5):548-60. PMID: 23826876.
      View in: PubMed
    46. Crawford ED. Rising PSA level in a 46-year-old man. Oncology (Williston Park). 2013 May; 27(5):394, 478. PMID: 25184261.
      View in: PubMed
    47. Rove KO, Crawford ED. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer. Curr Opin Urol. 2013 May; 23(3):208-13. PMID: 23492838.
      View in: PubMed
    48. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 04; 368(14):1314-25. PMID: 23550669; PMCID: PMC3682658.
    49. Barocas DA, Grubb R, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer. 2013 Jun 15; 119(12):2223-9. PMID: 23559420.
      View in: PubMed
    50. Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr; 13(2):261-70. PMID: 23570437.
      View in: PubMed
    51. Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC. Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr; 13(2):251-9. PMID: 23570436.
      View in: PubMed
    52. Tombal B, Crawford ED. Landmarks in hormonal therapy for prostate cancer. BJU Int. 2013 Mar; 111(3):E12-3. PMID: 23444930.
      View in: PubMed
    53. Tsilidis KK, Travis RC, Appleby PN, Allen NE, Lindström S, Albanes D, Ziegler RG, McCullough ML, Siddiq A, Barricarte A, Berndt SI, Bueno-de-Mesquita HB, Chanock SJ, Crawford ED, Diver WR, Gapstur SM, Giovannucci E, Gu F, Haiman CA, Hayes RB, Hunter DJ, Johansson M, Kaaks R, Kolonel LN, Kraft P, Le Marchand L, Overvad K, Polidoro S, Riboli E, Schumacher FR, Stevens VL, Trichopoulos D, Virtamo J, Willett WC, Key TJ. Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Int J Cancer. 2013 Jul 15; 133(2):495-504. PMID: 23341348; PMCID: PMC3656134.
    54. Andriole GL, McCullum-Hill C, Sandhu GS, Crawford ED, Barry MJ, Cantor A. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013 Feb; 189(2):486-92. PMID: 23253958; PMCID: PMC3979451.
    55. Crawford ED, Rove KO. Advanced prostate cancer: therapeutic sequencing, outcomes, and cost implications. Am J Manag Care. 2012 Dec; 18(5 Spec No.):SP250-3. PMID: 23301715.
      View in: PubMed
    56. Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013 May; 73(7):778-87. PMID: 23169245; PMCID: PMC4625901.
    57. Werahera PN, Sullivan K, La Rosa FG, Kim FJ, Lucia MS, O'Donnell C, Sidhu RS, Sullivan HT, Schulte B, Crawford ED. Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume. Int J Clin Exp Pathol. 2012; 5(9):892-9. PMID: 23119106; PMCID: PMC3484481.
    58. Crawford ED, Eisner J, Persson BE. Re: lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. T. M. van der Sluis, H. N. Bui, E. J. Meuleman, A. C. Heijboer, J. F. Hartman,N. van Adrichem, E. Boevé, W. de Ronde, R. J. van Moorselaar and A. N. Vis. J Urol 2012; 187: 1601–1607. J Urol. 2013 Mar; 189(3):1168-9. PMID: 23022003.
      View in: PubMed
    59. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, Huisman TK, Bilowus ML, Freedman SJ, Glover WL, Bostwick DG. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012 Nov; 188(5):1726-31. PMID: 22998901.
      View in: PubMed
    60. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012 Oct; 188(4):1164-9. PMID: 22921015; PMCID: PMC3481164.
    61. Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I, Parnes H. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer. 2013 Feb 01; 119(3):593-601. PMID: 22893105; PMCID: PMC3502695.
    62. Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED. Role of testosterone in managing advanced prostate cancer. Urology. 2012 Oct; 80(4):754-62. PMID: 22795376.
      View in: PubMed
    63. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012 Jun 21; 366(25):2345-57. PMID: 22612596; PMCID: PMC3641846.
    64. Rove KO, Crawford ED. Editorial comment. J Urol. 2012 Jun; 187(6):2049; discussion 2050. PMID: 22498224.
      View in: PubMed
    65. Berglund RK, Tangen CM, Powell IJ, Lowe BA, Haas GP, Carroll PR, Canby-Hagino ED, deVere White R, Hemstreet GP, Crawford ED, Thompson IM, Klein EA. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012 Mar; 79(3):633-7. PMID: 22386416; PMCID: PMC3839235.
    66. Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Doria-Rose VP, Laiyemo AO, Church T, Yokochi LA, Yurgalevitch S, Rathmell J, Andriole GL, Buys S, Crawford ED, Fouad M, Isaacs C, Lamerato L, Reding D, Prorok PC, Berg CD. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst. 2012 Feb 22; 104(4):280-9. PMID: 22298838; PMCID: PMC3283538.
    67. Lindström S, Schumacher FR, Cox D, Travis RC, Albanes D, Allen NE, Andriole G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Crawford ED, Diver WR, Gaziano JM, Giles GG, Giovannucci E, Gonzalez CA, Henderson B, Hunter DJ, Johansson M, Kolonel LN, Ma J, Le Marchand L, Pala V, Stampfer M, Stram DO, Thun MJ, Tjonneland A, Trichopoulos D, Virtamo J, Weinstein SJ, Willett WC, Yeager M, Hayes RB, Severi G, Haiman CA, Chanock SJ, Kraft P. Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):437-44. PMID: 22237985; PMCID: PMC3318963.
    68. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18; 104(2):125-32. PMID: 22228146; PMCID: PMC3260132.
    69. Crawford ED, Flaig TW. Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. Oncology (Williston Park). 2012 Jan; 26(1):70-7. PMID: 22393799.
      View in: PubMed
    70. Rove KO, Crawford ED. Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival. Oncology (Williston Park). 2011 Dec; 25(14):1362-70, 1375-81, 1387. PMID: 22329188.
      View in: PubMed
    71. Djavan B, Eastham J, Gomella L, Tombal B, Taneja S, Dianat SS, Kazzazi A, Shore N, Abrahamsson PA, Cheetham P, Moul J, Lepor H, Crawford ED. Testosterone in prostate cancer: the Bethesda consensus. BJU Int. 2012 Aug; 110(3):344-52. PMID: 22129242.
      View in: PubMed
    72. Rove KO, Crawford ED. Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts. World J Urol. 2012 Apr; 30(2):137-42. PMID: 22116599.
      View in: PubMed
    73. Higano CS, Crawford ED. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol. 2011 Nov-Dec; 29(6 Suppl):S1-8. PMID: 22074657.
      View in: PubMed
    74. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011 Nov 02; 306(17):1865-73. PMID: 22031728.
      View in: PubMed
    75. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011 Sep 28; 306(12):1344-51. PMID: 21954478; PMCID: PMC3326341.
    76. Werahera PN, Glode LM, La Rosa FG, Lucia MS, Crawford ED, Easterday K, Sullivan HT, Sidhu RS, Genova E, Hedlund T. Proliferative tumor doubling times of prostatic carcinoma. Prostate Cancer. 2011; 2011:301850. PMID: 22096656; PMCID: PMC3196972.
    77. Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. Cancer Prev Res (Phila). 2011 Nov; 4(11):1761-9. PMID: 21896650; PMCID: PMC3208719.
    78. Barqawi AB, Sullivan KF, Crawford ED, Roehrborn CG, Hughes A, O'Leary M, Stone N, O'Donnell CI. Methods of developing UWIN, the modified American Urological Association symptom score. J Urol. 2011 Sep; 186(3):940-4. PMID: 21791346.
      View in: PubMed
    79. Crawford ED, O'Donnell CI, Barqawi AB, O'Leary M, Sullivan KF, Hughes A, Roehrborn CG, Maroni P. Validation of the modified American Urological Association symptom score. J Urol. 2011 Sep; 186(3):945-8. PMID: 21791357.
      View in: PubMed
    80. Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, Mynderse LA, Roehrborn CG, Smith CP, Bruskewitz R. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011 Sep; 186(3):965-70. PMID: 21791356; PMCID: PMC3601655.
    81. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011 Sep; 186(3):889-97. PMID: 21788033.
      View in: PubMed
    82. Crawford ED, Phillips JM. Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res. 2011; 3:201-9. PMID: 21847353; PMCID: PMC3154964.
    83. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, Stevens VL, Chen C, Mondul AM, Travis RC, Stram DO, Eeles RA, Easton DF, Giles G, Hopper JL, Neal DE, Hamdy FC, Donovan JL, Muir K, Al Olama AA, Kote-Jarai Z, Guy M, Severi G, Grönberg H, Isaacs WB, Karlsson R, Wiklund F, Xu J, Allen NE, Andriole GL, Barricarte A, Boeing H, Bueno-de-Mesquita HB, Crawford ED, Diver WR, Gonzalez CA, Gaziano JM, Giovannucci EL, Johansson M, Le Marchand L, Ma J, Sieri S, Stattin P, Stampfer MJ, Tjonneland A, Vineis P, Virtamo J, Vogel U, Weinstein SJ, Yeager M, Thun MJ, Kolonel LN, Henderson BE, Albanes D, Hayes RB, Feigelson HS, Riboli E, Hunter DJ, Chanock SJ, Haiman CA, Kraft P. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011 Oct 01; 20(19):3867-75. PMID: 21743057; PMCID: PMC3168287.
    84. Crawford ED, Moul JW, Rove KO, Pettaway CA, Lamerato LE, Hughes A. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. BJU Int. 2011 Dec; 108(11):1743-9. PMID: 21711431.
      View in: PubMed
    85. Maroni P, Crawford ED. Assessment of men before androgen deprivation therapy. J Urol. 2011 Aug; 186(2):371-2. PMID: 21679987.
      View in: PubMed
    86. Barqawi AB, Turcanu R, Gamito EJ, Lucia SM, O'Donnell CI, Crawford ED, La Rosa DD, La Rosa FG. The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer. Int J Clin Exp Pathol. 2011 Jun 20; 4(5):468-75. PMID: 21738818; PMCID: PMC3127068.
    87. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun 08; 305(22):2295-303. PMID: 21642681.
      View in: PubMed
    88. Phillips JM, Crawford ED. Prostate-specific antigen (PSA) screening: has the pendulum swung too far? Asian J Androl. 2011 Sep; 13(5):655-6. PMID: 21602831; PMCID: PMC3739584.
    89. Berndt SI, Sampson J, Yeager M, Jacobs KB, Wang Z, Hutchinson A, Chung C, Orr N, Wacholder S, Chatterjee N, Yu K, Kraft P, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman C, Henderson B, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis RC, Kaaks R, Isaacs W, Isaacs S, Wiley KE, Gronberg H, Wiklund F, Stattin P, Xu J, Zheng SL, Sun J, Vatten LJ, Hveem K, Njølstad I, Gerhard DS, Tucker M, Hayes RB, Hoover RN, Fraumeni JF, Hunter DJ, Thomas G, Chanock SJ. Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet. 2011 Aug 15; 20(16):3322-9. PMID: 21576123; PMCID: PMC3140817.
    90. Barqawi AB, Rove KO, Gholizadeh S, O'Donnell CI, Koul H, Crawford ED. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol. 2011 Jul; 186(1):80-5. PMID: 21571335.
      View in: PubMed
    91. Croswell JM, Kramer BS, Crawford ED. Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park). 2011 May; 25(6):452-60, 463. PMID: 21717898.
      View in: PubMed
    92. Chung CC, Ciampa J, Yeager M, Jacobs KB, Berndt SI, Hayes RB, Gonzalez-Bosquet J, Kraft P, Wacholder S, Orr N, Yu K, Hutchinson A, Boland J, Chen Q, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Key TJ, Kaaks R, Isaacs WB, Isaacs SD, Grönberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Njolstad I, Gerhard DS, Tucker M, Hoover RN, Fraumeni JF, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ. Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet. 2011 Jul 15; 20(14):2869-78. PMID: 21531787; PMCID: PMC3118760.
    93. Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011 May 20; 29(15):2040-5. PMID: 21502546; PMCID: PMC3107759.
    94. Rove KO, Crawford ED. Dutasteride: novel milestones in prostate cancer chemoprevention. Drugs Today (Barc). 2011 Feb; 47(2):135-44. PMID: 21431101.
      View in: PubMed
    95. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2011 Sep; 108(5):693-9. PMID: 21105991; PMCID: PMC3117124.
    96. Crawford ED, Rove KO. Incomplete testosterone suppression in prostate cancer. N Engl J Med. 2010 Nov 11; 363(20):1976. PMID: 21067409.
      View in: PubMed
    97. Crawford ED, Grubb R, Black A, Andriole GL, Chen MH, Izmirlian G, Berg CD, D'Amico AV. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011 Feb 01; 29(4):355-61. PMID: 21041707; PMCID: PMC3058283.
    98. Akduman B, Tandberg DJ, O'Donnell CI, Hughes A, Moyad MA, Crawford ED. Effect of Statins on Serum Prostate-specific Antigen Levels. Urology. 2010 Nov; 76(5):1048-51. PMID: 20605197.
      View in: PubMed
    99. Crawford ED, Petrylak D. Castration-resistant prostate cancer: descriptive yet pejorative? J Clin Oncol. 2010 Aug 10; 28(23):e408. PMID: 20547989.
      View in: PubMed
    100. Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010 Jun 01; 70(8):848-55. PMID: 20127732.
      View in: PubMed
    101. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolonel LN, Tjønneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101. PMID: 20484221; PMCID: PMC2901143.
    102. Prokunina-Olsson L, Fu YP, Tang W, Jacobs KB, Hayes RB, Kraft P, Berndt SI, Wacholder S, Yu K, Hutchinson A, Spencer Feigelson H, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson BE, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Travis R, Kaaks R, Isaacs WB, Isaacs SD, Grönberg H, Wiklund F, Xu J, Vatten LJ, Hveem K, Kumle M, Tucker M, Hoover RN, Fraumeni JF, Hunter DJ, Thomas G, Chatterjee N, Chanock SJ, Yeager M. Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev. 2010 May; 19(5):1349-55. PMID: 20406958; PMCID: PMC2866032.
    103. Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Lamerato LE, Crawford ED, Kvale P, Fouad M, Hickey T, Riley T, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst. 2010 Apr 21; 102(8):538-46. PMID: 20357245; PMCID: PMC2857802.
    104. Koutros S, Schumacher FR, Hayes RB, Ma J, Huang WY, Albanes D, Canzian F, Chanock SJ, Crawford ED, Diver WR, Feigelson HS, Giovanucci E, Haiman CA, Henderson BE, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Le Marchand L, Riboli E, Siddiq A, Stampfer MJ, Stram DO, Thomas G, Travis RC, Thun MJ, Yeager M, Berndt SI. Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. Cancer Res. 2010 Mar 15; 70(6):2389-96. PMID: 20197460; PMCID: PMC2840184.
    105. Flaig TW, Kondo KL, La Rosa FG, Kavanagh B, Crawford ED. A young woman with multiple kidney lesions. Oncology (Williston Park). 2010 Mar; 24(3):282-6. PMID: 20394141.
      View in: PubMed
    106. Crawford ED, Black L, Eaddy M, Kruep EJ. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis. 2010 Jun; 13(2):162-7. PMID: 20125121.
      View in: PubMed
    107. Rove KO, Sullivan KF, Crawford ED. High-intensity focused ultrasound: ready for primetime. Urol Clin North Am. 2010 Feb; 37(1):27-35, Table of Contents. PMID: 20152517.
      View in: PubMed
    108. Shore ND, Crawford ED. Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol. 2010; 12(1):1-11. PMID: 20428288; PMCID: PMC2859136.
    109. Crawford ED, Andriole GL, Marberger M, Rittmaster RS. Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology. 2010 Mar; 75(3):502-9. PMID: 20035983.
      View in: PubMed
    110. Lee J, Andriole G, Avins A, Crawford ED, Foster H, Kaplan S, Kreder K, Kusek J, McCullough A, McVary K, Meleth S, Naslund M, Nickel JC, Nyberg L, Roehrborn C, Dale Williams O, Barry M. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clin Trials. 2009 Dec; 6(6):628-36. PMID: 20007408; PMCID: PMC3082919.
    111. Rove KO, Crawford ED. Metastatic cancer in solid tumors and clinical outcome: skeletal-related events. Oncology (Williston Park). 2009 Dec; 23(14 Suppl 5):21-7. PMID: 20128325.
      View in: PubMed
    112. Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010 May; 57(5):836-42. PMID: 19962227.
      View in: PubMed
    113. Schröder FH, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, Moul J, Olesen TK, Persson BE. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 2010 Jul; 106(2):182-7. PMID: 19912212.
      View in: PubMed
    114. Petrylak DP, Tangen CM, Van Veldhuizen PJ, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Crawford ED. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010 Feb; 105(3):317-21. PMID: 19888985.
      View in: PubMed
    115. Guo Y, Werahera PN, Narayanan R, Li L, Kumar D, Crawford ED, Suri JS. Image registration accuracy of a 3-dimensional transrectal ultrasound-guided prostate biopsy system. J Ultrasound Med. 2009 Nov; 28(11):1561-8. PMID: 19854971.
      View in: PubMed
    116. Yeager M, Chatterjee N, Ciampa J, Jacobs KB, Gonzalez-Bosquet J, Hayes RB, Kraft P, Wacholder S, Orr N, Berndt S, Yu K, Hutchinson A, Wang Z, Amundadottir L, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Haiman CA, Henderson B, Kolonel L, Le Marchand L, Siddiq A, Riboli E, Key TJ, Kaaks R, Isaacs W, Isaacs S, Wiley KE, Gronberg H, Wiklund F, Stattin P, Xu J, Zheng SL, Sun J, Vatten LJ, Hveem K, Kumle M, Tucker M, Gerhard DS, Hoover RN, Fraumeni JF, Hunter DJ, Thomas G, Chanock SJ. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet. 2009 Oct; 41(10):1055-7. PMID: 19767755; PMCID: PMC3430510.
    117. Roobol MJ, Schröder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, Andriole GL. A framework for the identification of men at increased risk for prostate cancer. J Urol. 2009 Nov; 182(5):2112-20. PMID: 19758625.
      View in: PubMed
    118. Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, Trump DL, Natale RB, Grossman HB, Crawford ED. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009 Sep 15; 115(18):4104-9. PMID: 19517476; PMCID: PMC3079554.
    119. Sullivan KF, Crawford ED. Targeted focal therapy for prostate cancer: a review of the literature. Ther Adv Urol. 2009 Aug; 1(3):149-59. PMID: 21789063; PMCID: PMC3126059.
    120. Crawford ED, Connor T. Proposed update on substaging metastatic prostate cancer. Urology. 2009 Jul; 74(1):237. PMID: 19567307.
      View in: PubMed
    121. Crawford ED, Hou AH. The role of LHRH antagonists in the treatment of prostate cancer. Oncology (Williston Park). 2009 Jun; 23(7):626-30. PMID: 19626830.
      View in: PubMed
    122. Mirabello L, Huang WY, Wong JY, Chatterjee N, Reding D, Crawford ED, De Vivo I, Hayes RB, Savage SA. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell. 2009 Aug; 8(4):405-13. PMID: 19493248; PMCID: PMC2742954.
    123. Crawford ED, Tangen CM. Clinical trials: 'clinical integration': laudable, but challenging. Nat Rev Urol. 2009 Jun; 6(6):297-8. PMID: 19498403.
      View in: PubMed
    124. Hou AH, Sullivan KF, Crawford ED. Targeted focal therapy for prostate cancer: a review. Curr Opin Urol. 2009 May; 19(3):283-9. PMID: 19357510.
      View in: PubMed
    125. Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med. 2009 May-Jun; 7(3):212-22. PMID: 19433838; PMCID: PMC2682972.
    126. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology. 2009 May; 73(5 Suppl):S4-10. PMID: 19375626.
      View in: PubMed
    127. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, Wacholder S, Chatterjee N, Feigelson HS, Thun MJ, Diver WR, Albanes D, Virtamo J, Weinstein S, Ma J, Gaziano JM, Stampfer M, Schumacher FR, Giovannucci E, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Crawford ED, Anderson SK, Tucker M, Hoover RN, Fraumeni JF, Thomas G, Hunter DJ, Dean M, Chanock SJ. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A. 2009 May 12; 106(19):7933-8. PMID: 19383797; PMCID: PMC2671324.
    128. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009 May 20; 27(15):2450-6. PMID: 19380444; PMCID: PMC2684851.
    129. deVere White RW, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MH, Crawford ED. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009 Jun; 181(6):2476-80; discussion 2480-1. PMID: 19371909; PMCID: PMC2769926.
    130. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26; 360(13):1310-9. PMID: 19297565; PMCID: PMC2944770.
    131. Grubb RL, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):748-51. PMID: 19258472.
      View in: PubMed
    132. Crawford ED. A review of the use of histrelin acetate in the treatment of prostate cancer. BJU Int. 2009 Mar; 103 Suppl 2:14-22. PMID: 19228148.
      View in: PubMed
    133. Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int. 2009 Aug; 104(3):310-4. PMID: 19239458.
      View in: PubMed
    134. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009 Mar; 181(3):956-62. PMID: 19167731; PMCID: PMC3510761.
    135. Dorff TB, Tangen CM, Crawford ED, Petrylak DP, Higano CS, Raghavan D, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. Ther Adv Med Oncol. 2009; 1(2):69-77. PMID: 21085622.
      View in: PubMed
    136. Lara PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009 Feb; 181(2):512-6; discussion 516-7. PMID: 19100570; PMCID: PMC3394523.
    137. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 07; 301(1):39-51. PMID: 19066370; PMCID: PMC3682779.
    138. Grubb RL, Pinsky PF, Greenlee RT, Izmirlian G, Miller AB, Hickey TP, Riley TL, Mabie JE, Levin DL, Chia D, Kramer BS, Reding DJ, Church TR, Yokochi LA, Kvale PA, Weissfeld JL, Urban DA, Buys SS, Gelmann EP, Ragard LR, Crawford ED, Prorok PC, Gohagan JK, Berg CD, Andriole GL. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008 Dec; 102(11):1524-30. PMID: 19035857.
      View in: PubMed
    139. Holyoak JD, Crawford ED, Meacham RB. Testosterone and the prostate: implications for the treatment of hypogonadal men. Curr Urol Rep. 2008 Nov; 9(6):500-5. PMID: 18947516.
      View in: PubMed
    140. Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol. 2008 Dec; 180(6):2453-7; discussion 2458. PMID: 18930488; PMCID: PMC3512115.
    141. Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, Van Veldhuizen PJ, Dakhil SR, Lara PN, Drelichman A, Hussain MH, Crawford ED. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer. 2008 Sep; 6(2):103-9. PMID: 18824433.
      View in: PubMed
    142. Shen F, Shinohara K, Kumar D, Khemka A, Simoneau AR, Werahera PN, Li L, Guo Y, Narayanan R, Wei L, Barqawi A, Crawford ED, Davatzikos C, Suri JS. Three-dimensional sonography with needle tracking: role in diagnosis and treatment of prostate cancer. J Ultrasound Med. 2008 Jun; 27(6):895-905. PMID: 18499849; PMCID: PMC3402711.
    143. Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford ED. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. 2008 Jun; 112(11):2393-400. PMID: 18383517; PMCID: PMC3359896.
    144. Crawford ED. Legends in urology. Can J Urol. 2008 Jun; 15(3):4044-6. PMID: 18570707.
      View in: PubMed
    145. Crawford ED, Abrahamsson PA. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol. 2008 Aug; 54(2):262-73. PMID: 18556114.
      View in: PubMed
    146. Conlon S, Tangen CM, Flanigan RC, Crawford ED, Lara PN. Predictors of survival in advanced renal cell carcinoma (RCC): Long-term results from Southwest Oncology Group trial S8949. J Clin Oncol. 2008 May 20; 26(15_suppl):5042. PMID: 27948903.
      View in: PubMed
    147. Lara PN, Goldman B, De Vere White R, Tangen CM, Smith DC, Wood D, Hussain MH, Crawford ED. A sequential treatment approach to muscle-invasive urothelial cancer: A phase II Southwest Oncology Group Trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG). J Clin Oncol. 2008 May 20; 26(15_suppl):5022. PMID: 27948829.
      View in: PubMed
    148. Hussain MH, Goldman B, Tangen CM, Higano CS, Petrylak DP, Crawford ED. Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916. J Clin Oncol. 2008 May 20; 26(15_suppl):5015. PMID: 27948853.
      View in: PubMed
    149. Pan C, Hussey M, Lara PN, Mack PC, Nagle R, Dutcher JP, Samlowski WE, Clark J, Gordon MS, Crawford ED. Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): Final results from Southwest Oncology Group study 0317. J Clin Oncol. 2008 May 20; 26(15_suppl):5051. PMID: 27948885.
      View in: PubMed
    150. Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford ED. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733. Cancer. 2008 May 15; 112(10):2181-7. PMID: 18404692.
      View in: PubMed
    151. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, Crawford ED, Andriole GL, Kaaks R, Hayes RB. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer. 2008 May 15; 122(10):2345-50. PMID: 18172860.
      View in: PubMed
    152. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, Sullivan H, Hedlund T, Crawford ED. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate. 2008 May 01; 68(6):620-8. PMID: 18213632.
      View in: PubMed
    153. Abouelfadel Z, Crawford ED. Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther Clin Risk Manag. 2008 Apr; 4(2):513-26. PMID: 18728847; PMCID: PMC2504071.
    154. Maroni PD, Crawford ED. The benefits of early androgen blockade. Best Pract Res Clin Endocrinol Metab. 2008 Apr; 22(2):317-29. PMID: 18471789.
      View in: PubMed
    155. Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glodé LM. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008 Mar 20; 26(9):1532-6. PMID: 18349405.
      View in: PubMed
    156. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009 Mar-Apr; 27(2):155-9. PMID: 18367117; PMCID: PMC2695968.
    157. Beer TM, Goldman B, Nichols CR, Petrylak DP, Agarwal M, Ryan CW, Crawford ED. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. Clin Genitourin Cancer. 2008 Mar; 6(1):36-9. PMID: 18501081.
      View in: PubMed
    158. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008 Mar; 40(3):310-5. PMID: 18264096.
      View in: PubMed
    159. Barqawi AB, Crawford ED. Emerging role of HIFU as a noninvasive ablative method to treat localized prostate cancer. Oncology (Williston Park). 2008 Feb; 22(2):123-9; discussion 129, 133, 137 passim. PMID: 18409659.
      View in: PubMed
    160. Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008 Jan 01; 26(1):112-20. PMID: 18165645.
      View in: PubMed
    161. Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Chia D, Crawford ED, Kaaks R, Hayes RB. IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer. 2007 Nov 15; 121(10):2267-73. PMID: 17597108.
      View in: PubMed
    162. La Rosa FG, Flaig TW, Wilson S, Crawford ED, Kim FJ. Sarcoidosis in a man with renal carcinoid tumor. Oncology (Williston Park). 2007 Nov; 21(13):1593-6. PMID: 18179048.
      View in: PubMed
    163. Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, Klein EA, Crawford ED. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol. 2007 Nov; 178(5):1946-51; discussion 1951. PMID: 17868721.
      View in: PubMed
    164. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA, Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19; 99(18):1375-83. PMID: 17848673.
      View in: PubMed
    165. Barqawi AB, Crawford ED. The current use and future trends of focal surgical therapy in the management of localized prostate cancer. Cancer J. 2007 Sep-Oct; 13(5):313-7. PMID: 17921730.
      View in: PubMed
    166. Crawford ED. Is a screening interval of every 4 years for prostate cancer acceptable? J Natl Cancer Inst. 2007 Sep 05; 99(17):1279-80. PMID: 17728212.
      View in: PubMed
    167. Ryan CW, Goldman BH, Lara PN, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007 Aug 01; 25(22):3296-301. PMID: 17664477.
      View in: PubMed
    168. Barqawi AB, Myers JB, O'Donnell C, Crawford ED. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. BJU Int. 2007 Oct; 100(4):853-7. PMID: 17662074.
      View in: PubMed
    169. Swanson GP, Carpenter WR, Thompson IM, Crawford ED. Urologists' attitudes regarding cancer clinical research. Urology. 2007 Jul; 70(1):19-24. PMID: 17656200.
      View in: PubMed
    170. Crawford ED, Thompson IM. Controversies regarding screening for prostate cancer. BJU Int. 2007 Jul; 100 Suppl 2:5-7. PMID: 17594348.
      View in: PubMed
    171. Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A. The association of time of day and serum testosterone concentration in a large screening population. BJU Int. 2007 Sep; 100(3):509-13. PMID: 17555474.
      View in: PubMed
    172. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007 Jun 01; 25(16):2225-9. PMID: 17538167.
      View in: PubMed
    173. Akduman B, Crawford ED. Bone metabolism and new targets for intervention. Curr Urol Rep. 2007 May; 8(3):233-8. PMID: 17459273.
      View in: PubMed
    174. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol. 2007 May; 177(5):1727-31. PMID: 17437798.
      View in: PubMed
    175. Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer. 2007 Apr 15; 109(8):1689-95. PMID: 17330856.
      View in: PubMed
    176. Flaig T, Crawford ED, Kavanagh B, Lucia S, La Rosa F, Barqawi A, Crighton F, Glodé LM. Prostate cancer in a man with multiple previous cancers. Oncology (Williston Park). 2007 Apr; 21(5):611-4. PMID: 17536345.
      View in: PubMed
    177. Maroni P, Crawford ED. Do tumor characteristics and prognostic factors differ between subsequent rounds of PSA screening for prostate cancer? Nat Clin Pract Urol. 2007 May; 4(5):252-3. PMID: 17389883.
      View in: PubMed
    178. Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007 Apr; 99(4):775-9. PMID: 17223921.
      View in: PubMed
    179. Crawford ED, Barqawi A. Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer. Oncology (Williston Park). 2007 Jan; 21(1):27-32; discussion 33-4, 39. PMID: 17313155.
      View in: PubMed
    180. Barqawi AB, Lu L, Crawford ED, Fenster A, Werahera PN, Kumar D, Miller S, Suri JS. Three different strategies for real-time prostate capsule volume computation from 3-D end-fire transrectal ultrasound. Conf Proc IEEE Eng Med Biol Soc. 2007; 2007:816-8. PMID: 18002081.
      View in: PubMed
    181. Peters U, Foster CB, Chatterjee N, Schatzkin A, Reding D, Andriole GL, Crawford ED, Sturup S, Chanock SJ, Hayes RB. Serum selenium and risk of prostate cancer-a nested case-control study. Am J Clin Nutr. 2007 Jan; 85(1):209-17. PMID: 17209198; PMCID: PMC1839923.
    182. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15; 296(19):2329-35. PMID: 17105795.
      View in: PubMed
    183. Crawford ED, Kavanagh BD. The role of alpha-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy. Am J Clin Oncol. 2006 Oct; 29(5):517-23. PMID: 17023790.
      View in: PubMed
    184. Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, Crawford ED. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncol Rep. 2006 Oct; 16(4):807-10. PMID: 16969498.
      View in: PubMed
    185. Swanson G, Thompson I, Basler J, Crawford ED. Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol. 2006 Oct; 176(4 Pt 1):1292-8. PMID: 16952615.
      View in: PubMed
    186. Xavier AC, Marshall C, La Rosa FG, Costa LJ, Drabkin H, Crawford ED. Woman with a papillary pulmonary lesion and a complex renal cyst. Oncology (Williston Park). 2006 Oct; 20(11):1437-9, 1443. PMID: 17112003.
      View in: PubMed
    187. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006 Aug 20; 24(24):3984-90. PMID: 16921051.
      View in: PubMed
    188. Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG, Crawford ED. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. Cancer. 2006 Aug 01; 107(3):489-96. PMID: 16804926.
      View in: PubMed
    189. Swanson GP, Faulkner J, Smalley SR, Noble MJ, Stephens RL, O'Rourke TJ, Weiss GR, Quick DP, Thompson IM, Crawford ED. Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. J Urol. 2006 Aug; 176(2):548-53; discussion 553. PMID: 16813886.
      View in: PubMed
    190. Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2006 Aug; 15(8):1479-84. PMID: 16896036.
      View in: PubMed
    191. Denberg TD, Glodé LM, Steiner JF, Crawford ED, Hoffman RM. Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU Int. 2006 Aug; 98(2):335-40. PMID: 16879674.
      View in: PubMed
    192. Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA, Andriole GL, Chia D, Levin DL, Gohagan JK. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology. 2006 Aug; 68(2):352-6. PMID: 16904451.
      View in: PubMed
    193. Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glodé LM. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer. 2006 Jul 15; 107(2):266-74. PMID: 16779800.
      View in: PubMed
    194. Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006 Jun 20; 24(18):2828-35. PMID: 16782921.
      View in: PubMed
    195. Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 2006 Jun 15; 106(12):2624-9. PMID: 16688776.
      View in: PubMed
    196. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21. PMID: 16622120.
      View in: PubMed
    197. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res. 2006 Apr 15; 66(8):4525-30. PMID: 16618781.
      View in: PubMed
    198. Morgentaler A, Rhoden EL, Barqawi AB, Crawford ED. Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove. J Urol. 2006 Apr; 175(4):1572; author reply 1573-4. PMID: 16516047.
      View in: PubMed
    199. Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol. 2006 Apr; 175(4):1286-90; discussion 1290. PMID: 16515981.
      View in: PubMed
    200. Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2178-84. PMID: 16609032.
      View in: PubMed
    201. Barqawi AB, Crawford ED. Re: Prostate cancer in men using testosterone supplementation. F. D. Gaylis, D. W. Lin, J. M. Ignatoff, C. L. Amling, R. F. Tutrone and D. J. Cosgrove. J Urol. 2006 Apr; 175(4):1572-3; author reply 1573-4. PMID: 16552901.
      View in: PubMed
    202. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006 Apr; 175(4):1422-6; discussion 1426-7. PMID: 16516013.
      View in: PubMed
    203. Maroni PD, Crawford ED. Screening for prostate cancer in 2006: PSA in the 21st century. N C Med J. 2006 Mar-Apr; 67(2):136-9. PMID: 16752718.
      View in: PubMed
    204. Kaplan SA, Crawford ED. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2006 Mar; 29(3):749; author reply 749-50. PMID: 16526124.
      View in: PubMed
    205. Akduman B, Crawford ED. Comparison of biochemical progression rates after radical prostatectomy and radiotherapy for localized prostate cancer. Nat Clin Pract Urol. 2006 Feb; 3(2):78-9. PMID: 16470204.
      View in: PubMed
    206. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2006 Feb; 175(2):533-6. PMID: 16406989.
      View in: PubMed
    207. Kirsh VA, Mayne ST, Peters U, Chatterjee N, Leitzmann MF, Dixon LB, Urban DA, Crawford ED, Hayes RB. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006 Jan; 15(1):92-8. PMID: 16434593.
      View in: PubMed
    208. Akduman B, Crawford ED. Treatment of localized prostate cancer. Rev Urol. 2006; 8 Suppl 2:S15-21. PMID: 17021637; PMCID: PMC1578714.
    209. Wilson SS, Crawford ED. Controversies of androgen ablation therapy for metastatic prostate cancer. Curr Pharm Des. 2006; 12(7):799-805. PMID: 16515496.
      View in: PubMed
    210. Unger JM, Coltman CA, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006 Jan 01; 24(1):141-4. PMID: 16330670.
      View in: PubMed
    211. Hussain M, Tangen CM, Lara PN, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol. 2005 Dec 01; 23(34):8724-9. PMID: 16314632.
      View in: PubMed
    212. Tewari A, Horninger W, Pelzer AE, Demers R, Crawford ED, Gamito EJ, Divine G, Johnson CC, Bartsch G, Menon M. Factors contributing to the racial differences in prostate cancer mortality. BJU Int. 2005 Dec; 96(9):1247-52. PMID: 16287439.
      View in: PubMed
    213. Crawford ED, Wilson SS, Torkko KC, Hirano D, Stewart JS, Brammell C, Wilson RS, Kawata N, Sullivan H, Lucia MS, Werahera PN. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int. 2005 Nov; 96(7):999-1004. PMID: 16225516.
      View in: PubMed
    214. Sarosdy MF, Tangen CM, Weiss GR, Nestok BR, Benson MC, Schellhammer PF, Sagalowsky AI, Wood DP, Crawford ED. A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study. Urol Oncol. 2005 Nov-Dec; 23(6):386-9. PMID: 16301114; PMCID: PMC3632328.
    215. Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer. 2005 Oct 15; 104(8):1627-32. PMID: 16138364.
      View in: PubMed
    216. Akduman B, Barqawi AB, Crawford ED. Minimally invasive surgery in prostate cancer: current and future perspectives. Cancer J. 2005 Sep-Oct; 11(5):355-61. PMID: 16259865.
      View in: PubMed
    217. Tewari A, Horninger W, Badani KK, Hasan M, Coon S, Crawford ED, Gamito EJ, Wei J, Taub D, Montie J, Porter C, Divine GW, Bartsch G, Menon M. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2005 Jul; 96(1):29-33. PMID: 15963115.
      View in: PubMed
    218. Crawford ED. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. BJU Int. 2005 Jun; 95 Suppl 4:1-5. PMID: 15871729.
      View in: PubMed
    219. Kumar RJ, Barqawi A, Crawford ED. Preventing and treating the complications of hormone therapy. Curr Urol Rep. 2005 May; 6(3):217-23. PMID: 15869726.
      View in: PubMed
    220. Canby-Hagino ED, Swanson GP, Crawford ED, Basler JW, Hernandez J, Thompson IM. Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated? Curr Urol Rep. 2005 May; 6(3):183-9. PMID: 15869722.
      View in: PubMed
    221. Porter CR, Gamito EJ, Crawford ED, Bartsch G, Presti JC, Tewari A, O'Donnell C. Model to predict prostate biopsy outcome in large screening population with independent validation in referral setting. Urology. 2005 May; 65(5):937-41. PMID: 15882727.
      View in: PubMed
    222. Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology. 2005 Apr; 65(4):708-12. PMID: 15833513.
      View in: PubMed
    223. Crawford ED. PSA testing: what is the use? Lancet. 2005 Apr 23-29; 365(9469):1447-9. PMID: 15850617.
      View in: PubMed
    224. Maroni PD, Crawford ED. Surgical management of prostate cancer: optimizing patient selections and clinical outcome. Surg Oncol Clin N Am. 2005 Apr; 14(2):301-19. PMID: 15817241.
      View in: PubMed
    225. Van Veldhuizen PJ, Faulkner JR, Lara PN, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol. 2005 Jul; 56(1):39-45. PMID: 15791454.
      View in: PubMed
    226. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005 Mar 16; 97(6):433-8. PMID: 15770007.
      View in: PubMed
    227. Barqawi A, Crawford ED. Focal therapy in prostate cancer: future trends. BJU Int. 2005 Feb; 95(3):273-4. PMID: 15679774.
      View in: PubMed
    228. Wilson SS, Crawford ED. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2005; 22:485-513. PMID: 16110626.
      View in: PubMed
    229. Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol. 2005; 7 Suppl 5:S37-43. PMID: 16985883; PMCID: PMC1477613.
    230. Beer TM, Tangen CM, Bland LB, Thompson IM, Crawford ED. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. J Urol. 2004 Dec; 172(6 Pt 1):2213-7. PMID: 15538234.
      View in: PubMed
    231. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 07; 351(15):1513-20. PMID: 15470214.
      View in: PubMed
    232. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004 Sep 01; 60(4):332-7. PMID: 15264245.
      View in: PubMed
    233. Crawford ED, Barqawi A. Intermediate- to high-risk prostate cancer patient treated with radiation therapy. Oncology (Williston Park). 2004 Aug; 18(9):1105-10. PMID: 15471196.
      View in: PubMed
    234. Werahera PN, Miller GJ, Torkko K, Crawford ED, Stewart JS, Deantoni EP, Miller HL, Lucia MS. Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models. Hum Pathol. 2004 Jul; 35(7):798-807. PMID: 15257542.
      View in: PubMed
    235. Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004 Jul 15; 22(14):2781-9. PMID: 15199091.
      View in: PubMed
    236. Ziada AM, Crawford ED. Radiation therapy after radical prostatectomy. ScientificWorldJournal. 2004 Jun 07; 4 Suppl 1:377-81. PMID: 15349561.
      View in: PubMed
    237. Herr HW, Faulkner JR, Grossman HB, Crawford ED. Pathologic evaluation of radical cystectomy specimens: a cooperative group report. Cancer. 2004 Jun 01; 100(11):2470-5. PMID: 15160354.
      View in: PubMed
    238. Wilson SS, Crawford ED. Screening for prostate cancer. Clin Prostate Cancer. 2004 Jun; 3(1):21-5. PMID: 15279686.
      View in: PubMed
    239. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004 May 27; 350(22):2239-46. PMID: 15163773.
      View in: PubMed
    240. Gamito EJ, Crawford ED. Artificial neural networks for predictive modeling in prostate cancer. Curr Oncol Rep. 2004 May; 6(3):216-21. PMID: 15066233.
      View in: PubMed
    241. Wilson SS, Crawford ED. Screening for prostate cancer: current recommendations. Urol Clin North Am. 2004 May; 31(2):219-26. PMID: 15123402.
      View in: PubMed
    242. Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol. 2004 Apr; 171(4):1513-9. PMID: 15017210.
      View in: PubMed
    243. Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Crawford ED, Glode LM. Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor. Cancer Res. 2004 Mar 15; 64(6):2090-5. PMID: 15026348.
      View in: PubMed
    244. Tewari A, Gamito EJ, Crawford ED, Menon M. Biochemical recurrence and survival prediction models for the management of clinically localized prostate cancer. Clin Prostate Cancer. 2004 Mar; 2(4):220-7. PMID: 15072605.
      View in: PubMed
    245. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004 Mar; 171(3):1071-6. PMID: 14767273.
      View in: PubMed
    246. Barqawi A, Thompson IM, Crawford ED. Prostate cancer chemoprevention: an overview of United States trials. J Urol. 2004 Feb; 171(2 Pt 2):S5-8; discussion S9. PMID: 14713745.
      View in: PubMed
    247. Barqawi A, Gamito E, O'Donnell C, Crawford ED. Herbal and vitamin supplement use in a prostate cancer screening population. Urology. 2004 Feb; 63(2):288-92. PMID: 14972473.
      View in: PubMed
    248. Thompson IM, Albanes D, Basler JW, Crawford ED, Denis LJ, Djavan B, Fleshner N, Johnson-Pais TL, Klein EA, Kristal AR, Lucia MS, Parnes HL, Piazza GA, Platz EA, Pollock BH, Price DK, Reichardt JK, Tangen CM, Tolcher AW, McMann MC. First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement. J Urol. 2004 Feb; 171(2 Pt 2):S3-4. PMID: 14713744.
      View in: PubMed
    249. Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria MV, Crawford ED. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol. 2004 Jan-Feb; 22(1):16-9. PMID: 14969798.
      View in: PubMed
    250. Crawford ED. Prostate cancer. Introduction. Urology. 2003 Dec 22; 62(6 Suppl 1):1-2. PMID: 14706502.
      View in: PubMed
    251. Crawford ED. Epidemiology of prostate cancer. Urology. 2003 Dec 22; 62(6 Suppl 1):3-12. PMID: 14706503.
      View in: PubMed
    252. Crawford ED. Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks. Urology. 2003 Dec 22; 62(6 Suppl 1):13-9. PMID: 14706504.
      View in: PubMed
    253. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18; 349(25):2387-98. PMID: 14681504.
      View in: PubMed
    254. Barqawi A, Akduman B, Abouelfadel Z, Robischon M, Crawford ED. The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. BJU Int. 2003 Nov; 92(7):695-8. PMID: 14616448.
      View in: PubMed
    255. Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology. 2003 Nov; 62(5):872-6. PMID: 14624911.
      View in: PubMed
    256. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003 Oct 15; 98(8):1643-8. PMID: 14534880.
      View in: PubMed
    257. Kawata N, Miller GJ, Crawford ED, Torkko KC, Stewart JS, Lucia MS, Miller HL, Hirano D, Werahera PN. Laterally directed biopsies detect more clinically threatening prostate cancer: computer simulated results. Prostate. 2003 Oct 01; 57(2):118-28. PMID: 12949935.
      View in: PubMed
    258. Porter CR, Crawford ED. Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer. Oncology (Williston Park). 2003 Oct; 17(10):1395-9; discussion 1399, 1403-6. PMID: 14606364.
      View in: PubMed
    259. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28; 349(9):859-66. PMID: 12944571.
      View in: PubMed
    260. Oottamasathien S, Crawford ED. Recent advances in hormonal therapy for advanced prostate cancer. Oncology (Williston Park). 2003 Aug; 17(8):1047-52; discussion 1054-8. PMID: 12966672.
      View in: PubMed
    261. Akduman B, Crawford ED. The management of high risk prostate cancer. J Urol. 2003 Jun; 169(6):1993-8. PMID: 12771704.
      View in: PubMed
    262. Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer. 2003 Jun; 2(1):41-5. PMID: 15046683.
      View in: PubMed
    263. Crawford ED. My total prostate-specific antigen (PSA) level is 0.2 nanograms per milliliter, which I'm told is normal. But my free-to-total PSA ratio is 8 percent, which I've read indicates a high risk of prostate cancer. What do these seemingly contradictory PSA results mean? Health News. 2003 Jun; 9(6):12. PMID: 12793407.
      View in: PubMed
    264. Crawford ED. A 42-year-old woman with breast cancer. Oncology (Williston Park). 2003 May; 17(5):614; discussion 615-20. PMID: 12800791.
      View in: PubMed
    265. Crawford ED, Wood DP, Petrylak DP, Scott J, Coltman CA, Raghavan D. Southwest Oncology Group studies in bladder cancer. Cancer. 2003 Apr 15; 97(8 Suppl):2099-108. PMID: 12673702.
      View in: PubMed
    266. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003 Apr 01; 21(7):1214-22. PMID: 12663707.
      View in: PubMed
    267. Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain RP, Miller G, Crawford ED, Kaplan SA, Sihelnik SA, Brawer MK, Lepor H. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2003 Apr; 24(2):224-43. PMID: 12689743.
      View in: PubMed
    268. Oottamasathien S, Crawford ED. Should routine screening for prostate-specific antigen be recommended? Arch Intern Med. 2003 Mar 24; 163(6):661-2; discussion 666. PMID: 12639195.
      View in: PubMed
    269. Crawford ED. Early versus late hormonal therapy: debating the issues. Urology. 2003 Feb; 61(2 Suppl 1):8-13. PMID: 12667882.
      View in: PubMed
    270. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003 Jan; 169(1):164-9. PMID: 12478127.
      View in: PubMed
    271. Crawford ED. The role of the urologist in treating patients with hormone-refractory prostate cancer. Rev Urol. 2003; 5 Suppl 2:S48-52. PMID: 16986047; PMCID: PMC1502331.
    272. Skeel RT, Huang J, Manola J, Wilding G, Dreicer R, Walker P, Muggia F, Crawford ED, Dutcher JP, Loehrer PJ. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). Cancer Invest. 2003; 21(1):41-6. PMID: 12643008.
      View in: PubMed
    273. Porter CR, O'Donnell C, Crawford ED, Gamito EJ, Sentizimary B, De Rosalia A, Tewari A. Predicting the outcome of prostate biopsy in a racially diverse population: a prospective study. Urology. 2002 Nov; 60(5):831-5. PMID: 12429310.
      View in: PubMed
    274. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVERE WHITE R, Thompson IM, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol. 2002 Nov; 168(5):2016-9. PMID: 12394698.
      View in: PubMed
    275. Gatenby RA, Gawlinski ET, Tangen CM, Flanigan RC, Crawford ED. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res. 2002 Sep 15; 62(18):5218-22. PMID: 12234987.
      View in: PubMed
    276. Abouelfadel Z, Miller GJ, Glode LM, Akduman B, Donohue RE, Nedrow A, Crawford ED. High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade. Clin Prostate Cancer. 2002 Sep; 1(2):115-7. PMID: 15046702.
      View in: PubMed
    277. Klein CE, Tangen CM, Braun TJ, Hussain MH, Peereboom DM, Nichols CR, Rivkin SE, Dakhil SR, Crawford ED. SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study. Prostate. 2002 Sep 01; 52(4):264-8. PMID: 12210486.
      View in: PubMed
    278. Thompson IM, Tangen C, Basler J, Crawford ED. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002 Sep; 168(3):1008-12. PMID: 12187210.
      View in: PubMed
    279. Crawford ED. A 72-year-old man with prostate cancer. Oncology (Williston Park). 2002 Aug; 16(8):1014-6, 1119-21. PMID: 12201642.
      View in: PubMed
    280. Crawford ED. Intravesical therapy for superficial cancer: need for more options. J Clin Oncol. 2002 Aug 01; 20(15):3185-6. PMID: 12149286.
      View in: PubMed
    281. Errejon A, Crawford ED. Monotherapy versus combined androgen blockade in patients with advanced prostate cancer. Cancer. 2002 Jul 15; 95(2):209-10. PMID: 12124816.
      View in: PubMed
    282. Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, Dakhil SR, Crawford ED. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. J Immunother. 2002 Jul-Aug; 25(4):352-8. PMID: 12142558.
      View in: PubMed
    283. Kelloff GJ, Higley HR, Brawer MK, Lucia MS, Sigman CC, Crawford ED. Chemoprevention strategies in the prostate: an overview. Rev Urol. 2002; 4(2):69-77. PMID: 16985658; PMCID: PMC1475973.
    284. Ziada AM, Lisle TC, Snow PB, Levine RF, Miller G, Crawford ED. Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. Cancer. 2001 Apr 15; 91(8 Suppl):1653-60. PMID: 11309764.
      View in: PubMed
    285. Suh CI, Shanafelt T, May DJ, Shroyer KR, Bobak JB, Crawford ED, Miller GJ, Markham N, Glode LM. Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol Cell Probes. 2000 Aug; 14(4):211-7. PMID: 10970725.
      View in: PubMed
    286. Crawford ED, Batuello JT, Snow P, Gamito EJ, McLeod DG, Partin AW, Stone N, Montie J, Stock R, Lynch J, Brandt J. The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma. Cancer. 2000 May 01; 88(9):2105-9. PMID: 10813722.
      View in: PubMed
    287. Crawford ED, Rosenblum M, Ziada AM, Lange PH. Hormone refractory prostate cancer. Urology. 1999 Dec; 54(6A Suppl):1-7. PMID: 10606277.
      View in: PubMed
    288. Crawford ED. Summary: the role of the urologist in chemotherapy of hormone refractory prostate cancer. Urology. 1999 Dec; 54(6A Suppl):51-2. PMID: 10606285.
      View in: PubMed
    289. Ziada A, Grover F, Crawford ED. The use of trans-oesophageal echocardiography in the management of intra-atrial thrombus in a patient with renal cell carcinoma. BJU Int. 1999 Oct; 84(6):737-8. PMID: 10510129.
      View in: PubMed
    290. Goktas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999 Apr; 26(2):162-73. PMID: 10597727.
      View in: PubMed
    291. Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999 Mar; 53(3 Suppl 3a):1-6. PMID: 10094094.
      View in: PubMed
    292. Crawford ED, Leewansangtong S, Goktas S, Holthaus K, Baier M. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate. 1999 Mar 01; 38(4):296-302. PMID: 10075009.
      View in: PubMed
    293. Crawford ED. The utility of prostate-specific antigen as a surrogate marker for identification of high-risk cohorts and assessing response in chemoprevention trials. Eur Urol. 1999; 35(5-6):511-4. PMID: 10325516.
      View in: PubMed
    294. Ziada AM, Crawford ED. Securing urethral catheters in patients undergoing urethrovesical anastomosis. Tech Urol. 1998 Dec; 4(4):210-1. PMID: 9892004.
      View in: PubMed
    295. Leewansangtong S, Goktas S, Lepoff R, Holthaus K, Crawford ED. Comparability of serum prostate-specific antigen measurement between the hybritech Tandem-R and Abbott AxSYM assays. Urology. 1998 Sep; 52(3):467-9. PMID: 9730462.
      View in: PubMed
    296. Stenner J, DeAntoni EP, O'Donnell C, Stone NN, McLeod DG, Crawford ED. Prevalence and natural history of urinary symptoms in a longitudinal national prostate cancer screening (community-based) study. Prostate Cancer Prostatic Dis. 1998 Sep; 1(5):256-261. PMID: 12496885.
      View in: PubMed
    297. Crawford ED, Hirano D, Werahera PN, Lucia MS, DeAntoni EP, Daneshgari F, Brawn PN, Speights VO, Stewart JS, Miller GJ. Computer modeling of prostate biopsy: tumor size and location--not clinical significance--determine cancer detection. J Urol. 1998 Apr; 159(4):1260-4. PMID: 9507848.
      View in: PubMed
    298. Hirano D, Werahera PN, Crawford ED, Lucia MS, DeAntoni EP, Miller GJ. Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy. J Urol. 1998 Apr; 159(4):1265-9. PMID: 9507849.
      View in: PubMed
    299. Stenner J, Holthaus K, Mackenzie SH, Crawford ED. The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology. 1998 Mar; 51(3):455-9. PMID: 9510352.
      View in: PubMed
    300. DeAntoni EP, Göktas S, Stenner J, O'Donnell C, Crawford ED. A cross-sectional study of vasectomy, time since vasectomy and prostate cancer. Prostate Cancer Prostatic Dis. 1997 Dec; 1(2):73-78. PMID: 12496919.
      View in: PubMed
    301. Crawford ED, Bennett CL, Stone NN, Knight SJ, DeAntoni E, Sharp L, Garnick MB, Porterfield HA. Comparison of perspectives on prostate cancer: analyses of survey data. Urology. 1997 Sep; 50(3):366-72. PMID: 9301699.
      View in: PubMed
    302. Crawford ED. Prostate Cancer Awareness Week: September 22 to 28, 1997. CA Cancer J Clin. 1997 Sep-Oct; 47(5):288-96. PMID: 9314823.
      View in: PubMed
    303. Crawford ED, DeAntoni EP, Hussain M, Thompson IM, Coltman CA. Prostate cancer clinical trials of the Southwest Oncology Group. Oncology (Williston Park). 1997 Aug; 11(8):1154-63; discussion 1163-70. PMID: 9268978.
      View in: PubMed
    304. Nishiya M, Crawford ED. Perineal cystoprostatectomy and ureterosigmoidostomy for invasive bladder cancer. J Urol. 1997 Jun; 157(6):2227-9. PMID: 9146622.
      View in: PubMed
    305. Waxman S, Stevens AK, Walsh RA, Mackenzie SH, Crawford ED. Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Oncology (Williston Park). 1997 Apr; 11(4):457-60, 465; discussion 465-6, 469. PMID: 9130270.
      View in: PubMed
    306. Crawford ED. Prostate cancer: to screen or not to screen? Oncology (Williston Park). 1997 Jan; 11(1):50, 55-6, 59. PMID: 9115852.
      View in: PubMed
    307. DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, Staggers F, Stone NN. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology. 1996 Aug; 48(2):234-9. PMID: 8753735.
      View in: PubMed
    308. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology. 1996 Jun; 47(6):863-9. PMID: 8677578.
      View in: PubMed
    309. Crawford ED. Diagnosis and treatment of superficial bladder cancer: an update. Semin Urol Oncol. 1996 Feb; 14(1 Suppl 1):1-9. PMID: 8727804.
      View in: PubMed
    310. Crawford ED, DeAntoni EP, Ross CA. The role of prostate-specific antigen in the chemoprevention of prostate cancer. J Cell Biochem Suppl. 1996; 25:149-55. PMID: 9027612.
      View in: PubMed
    311. Crawford ED. Combined androgen blockade. Eur Urol. 1996; 29 Suppl 2:54-61. PMID: 8717465.
      View in: PubMed
    312. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol. 1995 Dec; 154(6):1991-8. PMID: 7500443.
      View in: PubMed
    313. DeAntoni E, Crawford ED. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma]. Urologe A. 1995 Sep; 34(5):382-8. PMID: 7483154.
      View in: PubMed
    314. Grampsas SA, Miller GJ, Crawford ED. Salvage radical prostatectomy after failed transperineal cryotherapy: histologic findings from prostate whole-mount specimens correlated with intraoperative transrectal ultrasound images. Urology. 1995 Jun; 45(6):936-41. PMID: 7771026.
      View in: PubMed
    315. Cox RL, Crawford ED. Complications of cryosurgical ablation of the prostate to treat localized adenocarcinoma of the prostate. Urology. 1995 Jun; 45(6):932-5. PMID: 7771025.
      View in: PubMed
    316. Daneshgari F, Taylor GD, Miller GJ, Crawford ED. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology. 1995 Apr; 45(4):604-9. PMID: 7716840.
      View in: PubMed
    317. Crawford ED, DeAntoni EP. Current status of combined androgen blockade: optimal therapy for advanced prostate cancer. J Clin Endocrinol Metab. 1995 Apr; 80(4):1062-6. PMID: 7714067.
      View in: PubMed
    318. Crawford ED, Hussain M, DeAntoni EP, Thompson IM, Eisenberger MA, Blumenstein B, Coltman CA. Southwest Oncology Group strategies in prostatic carcinoma. Semin Surg Oncol. 1995 Jan-Feb; 11(1):60-4. PMID: 7754277.
      View in: PubMed
    319. Waxman SW, Crawford ED. Advanced prostate cancer. Surg Technol Int. 1995; IV:266-70. PMID: 21400446.
      View in: PubMed
    320. Nishiya M, Miller GJ, Lookner DH, Crawford ED. Prostate specific antigen density in patients with histologically proven prostate carcinoma. Cancer. 1994 Dec 01; 74(11):3002-9. PMID: 7525041.
      View in: PubMed
    321. Mayer FJ, Crawford ED. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. Urol Clin North Am. 1994 Nov; 21(4):707-15. PMID: 7974899.
      View in: PubMed
    322. DeAntoni EP, Crawford ED. Pretreatment of metastatic disease. Prostate cancer in the older male. Cancer. 1994 Oct 01; 74(7 Suppl):2182-7. PMID: 8087788.
      View in: PubMed
    323. Crawford ED, Kozlowski JM, Debruyne FM, Fair WR, Logothetis CJ, Balmer C, Robinson RG, Porter AT, Kirk D. The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology. 1994 Oct; 44(4):481-5. PMID: 7524233.
      View in: PubMed
    324. Grampsas SA, Kahn K, Crawford ED. Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer. Online J Curr Clin Trials. 1994 Mar 03; Doc No 117:[4845 words; 36 paragraphs]. PMID: 8136939.
      View in: PubMed
    325. Andros EA, Danesghari F, Crawford ED. Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med. 1993 Dec; 16(6):510-5. PMID: 7516835.
      View in: PubMed
    326. DeAntoni E, Crawford ED, Stone NN, Blum DS, Berger ER, Eisenberger MA, Gambert SR, Staggers F. Prostate Cancer Awareness Week, 1992: a summary of key findings. Clin Invest Med. 1993 Dec; 16(6):448-57. PMID: 7516833.
      View in: PubMed
    327. Crawford ED, DeAntoni EP. PSA as a screening test for prostate cancer. Urol Clin North Am. 1993 Nov; 20(4):637-46. PMID: 7505971.
      View in: PubMed
    328. Daneshgari F, Crawford ED. Benign prostatic disease. A growing challenge in the 1990s. Postgrad Med. 1993 May 15; 93(7):84-92. PMID: 7684136.
      View in: PubMed
    329. Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer. 1993 Feb 01; 71(3 Suppl):1089-97. PMID: 8428333.
      View in: PubMed
    330. Crawford ED, Daneshgari F, Majeski SA. Etoposide in the treatment of hormone-refractory advanced carcinoma of the prostate. Semin Oncol. 1992 Dec; 19(6 Suppl 14):53-7. PMID: 1488654.
      View in: PubMed
    331. Seligman PA, Moran PL, Schleicher RB, Crawford ED. Treatment with gallium nitrate: evidence for interference with iron metabolism in vivo. Am J Hematol. 1992 Dec; 41(4):232-40. PMID: 1337663.
      View in: PubMed
    332. Crawford ED. Challenges in the management of prostate cancer. Br J Urol. 1992 Nov; 70 Suppl 1:33-8. PMID: 1467876.
      View in: PubMed
    333. Crawford ED, Goodman P, Nabors WL, Stephens RL, Khan K, Pass LM, Smith AY, Christie DW. Treatment of stages B3 and C seminoma with chemotherapy followed by irradiation therapy. Southwest Oncology Group Study. Urology. 1992 May; 39(5):457-60. PMID: 1580039.
      View in: PubMed
    334. Crawford ED, Daneshgari F. Management of regional lymphatic drainage in carcinoma of the penis. Urol Clin North Am. 1992 May; 19(2):305-17. PMID: 1574821.
      View in: PubMed
    335. Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, Gomella LG, Austenfeld M, Stone NN, Miles BJ, et al. The effect of digital rectal examination on prostate-specific antigen levels. JAMA. 1992 Apr 22-29; 267(16):2227-8. PMID: 1372943.
      View in: PubMed
    336. Crawford ED, Berger NS, Davis MA, Donohue RE. Prevention of urinary tract infection and bacteremia following transurethral surgery: oral lomefloxacin compared to parenteral cefotaxime. J Urol. 1992 Apr; 147(4):1053-5. PMID: 1313116.
      View in: PubMed
    337. Crawford ED, Fair WR, Kelloff GJ, Lieber MM, Miller GJ, Scardíno PT, DeAntoni EP. Chemoprevention of prostate cancer: guidelines for possible intervention strategies. J Cell Biochem Suppl. 1992; 16H:140-5. PMID: 1337764.
      View in: PubMed
    338. Seligman PA, Crawford ED. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst. 1991 Nov 06; 83(21):1582-4. PMID: 1960756.
      View in: PubMed
    339. Crawford ED. Benign and malignant prostatic diseases. Am Fam Physician. 1991 Nov; 44(5 Suppl):65S-70S. PMID: 1950983.
      View in: PubMed
    340. Crawford ED, Saiers JH, Baker LH, Costanzi JH, Bukowski RM. Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study. Urology. 1991 Oct; 38(4):355-7. PMID: 1755146.
      View in: PubMed
    341. Crawford ED, Nabors WL. Total androgen ablation: American experience. Urol Clin North Am. 1991 Feb; 18(1):55-63. PMID: 1899495.
      View in: PubMed
    342. Philpott AC, Crawford ED, Miller GJ. A new method for assaying antimicrobials in the prostate. Infection. 1991; 19 Suppl 3:S150-3. PMID: 2055651.
      View in: PubMed
    343. Crawford ED, Allen JA. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036. J Steroid Biochem Mol Biol. 1990 Dec 20; 37(6):961-3. PMID: 2126738.
      View in: PubMed
    344. Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA. Leuprolide with and without flutamide in advanced prostate cancer. Cancer. 1990 Sep 01; 66(5 Suppl):1039-44. PMID: 2118417.
      View in: PubMed
    345. Crawford ED. Hormonal therapy of prostatic carcinoma. Defining the challenge. Cancer. 1990 Sep 01; 66(5 Suppl):1035-8. PMID: 2203516.
      View in: PubMed
    346. Lile R, Thickman D, Miller GJ, Crawford ED. Prostatic comedocarcinoma: correlation of sonograms with pathologic specimens in three cases. AJR Am J Roentgenol. 1990 Aug; 155(2):303-6. PMID: 2164763.
      View in: PubMed
    347. Crawford ED, Goodman P, Blumenstein B. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo. Semin Urol. 1990 Aug; 8(3):154-8. PMID: 2119048.
      View in: PubMed
    348. Nabors W, Crawford ED. Luteinizing hormone releasing hormone agonists: the US experience. J Int Med Res. 1990; 18 Suppl 1:31-4. PMID: 2108884.
      View in: PubMed
    349. Crawford ED. Combination studies with leuprolide. Eur Urol. 1990; 18 Suppl 3:30-3. PMID: 2128828.
      View in: PubMed
    350. Crawford ED, Natale RB, Burton H. Southwest Oncology Group Study 8710: trial of cystectomy alone versus neo-adjuvant M-VAC and cystectomy in patients with locally advanced bladder cancer (Intergroup Trial 0080). Prog Clin Biol Res. 1990; 353:111-3. PMID: 2217407.
      View in: PubMed
    351. Crawford ED. Combined androgen blockade. Urology. 1989 Oct; 34(4 Suppl):22-6; discussion 46-56. PMID: 2508291.
      View in: PubMed
    352. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989 Aug 17; 321(7):419-24. PMID: 2503724.
      View in: PubMed
    353. Crawford ED. The role of ultrasound in prostatic imaging. Introduction and overview. Urology. 1989 Jun; 33(6 Suppl):2-6. PMID: 2658245.
      View in: PubMed
    354. Foote JE, Crawford ED. Total androgen suppression: are there any advantages? The use of combined therapy in the treatment of advanced prostate adenocarcinoma. Semin Urol. 1988 Nov; 6(4):291-302. PMID: 3068767.
      View in: PubMed
    355. Crawford ED, Das S, Smith JA. Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin North Am. 1987 Nov; 14(4):781-7. PMID: 3314069.
      View in: PubMed
    Crawford's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)